Summary: MASH treatment has changed quickly. MASLD is fatty liver disease in the setting of metabolic risk factors; MASH is the inflammatory, injury-producing form that can progress to fibrosis and cirrhosis. Treatment still begins with cardiometabolic risk reduction, but resmetirom created the first FDA-approved liver-directed drug option for adults with noncirrhotic MASH/NASH and moderate to advanced fibrosis.
For years, fatty liver pages could only say that treatment centered on weight loss, exercise, diabetes care, lipid management, and risk-factor control. Those still matter. The difference now is that MASH with significant fibrosis has entered a more active treatment era, with noninvasive testing, fibrosis staging, resmetirom, and incretin-based therapies all shaping clinical decisions.
The FDA approved resmetirom in March 2024 for use with diet and exercise in adults with noncirrhotic NASH with moderate to advanced liver fibrosis. Many liver societies now use MASH terminology for the same inflammatory metabolic liver disease. Resmetirom is a liver-directed thyroid hormone receptor beta agonist and is used in carefully selected patients rather than in every person with simple steatosis.
The 2024 EASL-EASD-EASO MASLD guideline states that, where approved and label-dependent, adults with noncirrhotic MASH and significant fibrosis should be considered for resmetirom as a MASH-targeted therapy. The guideline also notes that no MASH-targeted pharmacotherapy can currently be recommended for cirrhotic-stage MASH.
Incretin-based therapy also matters because obesity and type 2 diabetes are major drivers of MASLD and MASH progression. ADA 2026 guidance supports GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists in selected patients with type 2 diabetes, overweight or obesity, and MASLD/MASH context. These medicines may improve weight, glycemia, and cardiometabolic risk while also influencing liver-fat biology.
Treatment decisions depend on identifying who is most likely to have clinically significant fibrosis. That is why FIB-4, transient elastography, MR elastography, ELF testing, platelet count, age, diabetes status, and liver enzymes are part of the modern MASLD pathway. The purpose is not to label every fatty liver as advanced disease; the purpose is to find the subset at higher risk for liver-related outcomes.
MASLD | MASLD Screening: FIB-4 and Liver Stiffness | De Novo Lipogenesis | GLP-1 and GIP Therapy | Obesity
© 2026 Internets. All rights reserved.